GlassScriptPhysician profile
Elmer G Smith
NPI 1699793992
$15,914.83
in general payments reported to CMS, 2019-2025
60 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,072 · 2020: $1,951 · 2021: $2,493 · 2022: $2,294 · 2023: $2,585 · 2024: $2,370 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,958 · Education: $96.71 · Long Term Medical Supply Or Device Loan: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,958.15 |
| Education | $96.71 |
| Long Term Medical Supply Or Device Loan | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,294.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,272.94 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,113.88 | 2019-2025 | Repatha, Evenity, Repatha |
| Otsuka America Pharmaceutical, INC. | $845.32 | 2021-2025 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $807.52 | 2021-2025 | |
| Abbvie INC. | $786.14 | 2020-2025 | Vraylar |
| Lilly USA, LLC | $699.19 | 2020-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $665.04 | 2019-2025 | Jardiance |
| Sunovion Pharmaceuticals INC. | $663.08 | 2019-2021 | |
| Pfizer INC. | $621.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $599.90 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $530.32 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbott Laboratories | $509.09 | 2019-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $491.26 | 2020-2025 | Caplyta |
| Astellas Pharma US INC | $442.50 | 2019-2025 | Veozah |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $379.85 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $359.22 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $299.52 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $295.54 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.30 | 2019-2024 | Cycloset, Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $257.62 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Corcept Therapeutics | $192.43 | 2022-2024 | Korlym |
| Antares Pharma, INC. | $178.26 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Dexcom, INC. | $176.22 | 2021-2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $167.45 | 2024 | Gemtesa |
| Smith+Nephew, INC. | $141.38 | 2021 | |
| Acadia Pharmaceuticals INC | $137.96 | 2019-2025 | Nuplazid |
| Evoke Pharma, INC. | $128.86 | 2020-2022 | |
| Lundbeck LLC | $126.72 | 2023-2024 | Rexulti |
| Genentech, INC. | $109.91 | 2019 | |
| Exact Sciences Corporation | $107.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Avanir Pharmaceuticals, INC. | $80.47 | 2019-2021 | |
| Shield Therapeutics INC | $76.33 | 2024 | |
| Ucb, INC. | $76.31 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $75.70 | 2021-2022 | |
| Sage Therapeutics, LLC | $72.36 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.27 | 2022 | |
| Medtronic, INC. | $66.57 | 2024 | Venaseal |
| Idorsia Pharmaceuticals US INC | $62.65 | 2022-2023 | Quviviq |
| Avvisto Therapeutics, LLC | $61.77 | 2025 | Cycloset |
| Sanofi-Aventis U.S. LLC | $61.06 | 2019-2022 | |
| Sk Life Science, INC. | $56.16 | 2025 | |
| Acorda Therapeutics, INC | $47.72 | 2019 | |
| Harmony Biosciences LLC | $45.70 | 2020 | |
| Biogen, INC. | $45.27 | 2020-2021 | |
| Globus Medical, INC. | $39.31 | 2025 | Senza |
| Halozyme INC | $38.10 | 2023 | |
| Arbor Pharmaceuticals, INC. | $33.30 | 2019-2022 | |
| Seqirus USA INC | $32.30 | 2022 | |
| Allergan, INC. | $29.15 | 2020 | |
| Axsome Therapeutics, INC. | $23.95 | 2025 | Sunosi |
| Genentech USA, INC. | $21.10 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $21.05 | 2022 | |
| Neurocrine Biosciences, INC. | $20.70 | 2025 | |
| Baxter Healthcare | $17.97 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Mannkind Corporation | $17.96 | 2019 | |
| Cmp Pharma, INC. | $16.27 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.99 | 2024 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $11.88 | 2020 | |
| Mylan Specialty L.P. | $11.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elmer Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.